Search
Search Results
##search.searchResults.foundPlural##
-
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1575PDF: 1207HTML: 189 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3298PDF: 1342HTML: 2625 -
Coronavirus disease 2019 (COVID-19) severity in patients with thalassemias: A Nationwide Iranian Experience Coronavirus in patients with thalassemias
1350PDF: 469HTML: 168 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1767PDF: 1072HTML: 249 -
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large b-cell lymphoma.
3348PDF: 1028HTML: 1005Figure 1: 170 -
CLINICAL AND LABORATORY FEATURES OF SICKLE CELL DISEASE S/D PUNJAB: IMPACT OF HBF AND HYDROXYUREA SCD S/D Punjab
1321PDF: 1128HTML: 119 -
-
-
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2193PDF: 1488HTML: 266 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
1721PDF: 769HTML: 508 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
806PDF: 422HTML: 285 -
CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
2875PDF: 1099HTML: 3029 -
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
1277PDF: 762HTML: 4376Figure 1: 155Untitled: 129Untitled: 184 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1340PDF: 826HTML: 132 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
1998PDF: 1133HTML: 626 -
Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19
3192PDF: 1580HTML: 258 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1242PDF: 985HTML: 211 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
1961PDF: 811HTML: 221 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4102PDF: 1587HTML: 952 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3219PDF: 1430HTML: 5845Fig1-Ag-Pil: 226Ag-Pil Fig.2: 227 -
THE SYSTEMIC MASTOCYTOSIS: RADIOLOGICAL POINT OF VIEW Systemic mastocytosis
1495PDF: 542HTML: 716 -
ANORECTAL PATHOLOGIES IN THE COURSE OF ACUTE LEUKAEMIAS: PREDICTIVE PARAMETERS Anorectal pathologies in leukemias
1180PDF: 726Html: 96 -
Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited
1083PDF: 843HTML: 238 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1966PDF: 748HTML: 694 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1663PDF: 1177HTML: 201 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2489PDF: 922HTML: 529 -
-
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia
1045PDF: 1336HTML: 106 -
CHILDREN IN CORONAVIRUSES’ WONDERLAND: WHAT CLINICIANS NEED TO KNOW Corona virus and Children
1424PDF: 936HTML: 324 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3548PDF: 1571HTML: 80 -
EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF PEDIATRIC COVID-19 IN THE TERTIARY CARE SYSTEM IN THAILAND: COMPARATIVE DELTA AND PRE-DELTA ERA Pediatric COVID-19 in Thailand during pre-Delta and Delta era
1049PDF: 583HTML: 218 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3259PDF: 1089HTML: 437







